[Medical Observer Reporter Hyung-Joo Shin] REV-MED is accelerating the expansion of its business operations by actively leveraging the broadened clinical research scope and simplified approval procedures introduced through the amendment to the “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act.”
In particular, the amendment has expanded the application scope of advanced regenerative medicine beyond severe, rare, and intractable diseases to include general medical conditions, allowing REV-MED’s proprietary autologous biological extraction technologies to be utilized more broadly.
As part of this initiative, REV-MED has established a state-of-the-art cell processing facility at its new headquarters, presenting a clear vision to lead the regenerative medicine industry.
The company has also obtained certifications in Japan and China based on its independently developed triple-chamber technology — a rare achievement among Korean biotechnology companies.
In addition, REV-MED has developed bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has gained recognition in the global market for its technological reliability and innovation.
These technological strengths are expected to drive rapid revenue growth in conjunction with the expanded clinical and therapeutic-use approval procedures enabled by the revised legislation.
As a result of the regulatory changes, REV-MED’s autologous biological extraction technologies and bio-kit product lines are now positioned to be utilized across a broader market landscape.
The amendment has opened a pathway for limited patient administration during clinical stages through treatment-purpose approval procedures, enabling revenue generation even during the early phases of research.
To strengthen credibility, REV-MED has published approximately 20 SCI(E)-level academic papers. These scholarly activities are regarded as supporting the company’s technological expertise while contributing to trust-building in the global market.
The global biological products market is projected to grow at an annual rate of over 10%, reaching approximately USD 615 billion by 2029.
Targeting this growth, REV-MED has designated 2025 as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
In particular, as Korea’s regenerative medicine market becomes increasingly activated following the amendment to the Advanced Regenerative Medicine Act, the company plans to expand its market share in both domestic and international markets simultaneously.
A company representative stated, “This amendment to the Advanced Regenerative Medicine Act represents an important turning point that creates new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”
Source: Medical Observer
[Medical Observer Reporter Hyung-Joo Shin] REV-MED is accelerating the expansion of its business operations by actively leveraging the broadened clinical research scope and simplified approval procedures introduced through the amendment to the “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act.”
In particular, the amendment has expanded the application scope of advanced regenerative medicine beyond severe, rare, and intractable diseases to include general medical conditions, allowing REV-MED’s proprietary autologous biological extraction technologies to be utilized more broadly.
As part of this initiative, REV-MED has established a state-of-the-art cell processing facility at its new headquarters, presenting a clear vision to lead the regenerative medicine industry.
The company has also obtained certifications in Japan and China based on its independently developed triple-chamber technology — a rare achievement among Korean biotechnology companies.
In addition, REV-MED has developed bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has gained recognition in the global market for its technological reliability and innovation.
These technological strengths are expected to drive rapid revenue growth in conjunction with the expanded clinical and therapeutic-use approval procedures enabled by the revised legislation.
As a result of the regulatory changes, REV-MED’s autologous biological extraction technologies and bio-kit product lines are now positioned to be utilized across a broader market landscape.
The amendment has opened a pathway for limited patient administration during clinical stages through treatment-purpose approval procedures, enabling revenue generation even during the early phases of research.
To strengthen credibility, REV-MED has published approximately 20 SCI(E)-level academic papers. These scholarly activities are regarded as supporting the company’s technological expertise while contributing to trust-building in the global market.
The global biological products market is projected to grow at an annual rate of over 10%, reaching approximately USD 615 billion by 2029.
Targeting this growth, REV-MED has designated 2025 as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
In particular, as Korea’s regenerative medicine market becomes increasingly activated following the amendment to the Advanced Regenerative Medicine Act, the company plans to expand its market share in both domestic and international markets simultaneously.
A company representative stated, “This amendment to the Advanced Regenerative Medicine Act represents an important turning point that creates new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”
Source: Medical Observer